We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
Consensus vs. actual, and revenue trend
Consensus PT $949.73 · 15 analysts
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
Stored first · Google News · Yahoo Finance (English)
McKesson’s ASCO 2026 Data Highlights Evolving Role In Community Oncology - simplywall.st
McKesson’s ASCO 2026 Data Highlights Evolving Role In Community Oncology simplywall.st
McKesson Expands Gene Therapy Role With Nanoscope InspiroGene Partnership - simplywall.st
McKesson Expands Gene Therapy Role With Nanoscope InspiroGene Partnership simplywall.st
Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), McKesson (MCK) and Biohaven Ltd. (BHVN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), McKesson (MCK) and Biohaven Ltd. (BHVN) The Globe and Mail
Owens & Minor names former McKesson VP as new CEO - MassDevice
Owens & Minor names former McKesson VP as new CEO MassDevice
Assessing McKesson (MCK) Valuation After Recent Share Price Weakness And Cooling Long Term Momentum - simplywall.st
Assessing McKesson (MCK) Valuation After Recent Share Price Weakness And Cooling Long Term Momentum simplywall.st
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | After market close (AMC) | $9.58 | — | — | $103.99B | — | Scheduled |
| FY2026 Q3 | 2026. 02. 04. | Time TBD | — | $15.8 | — | — | $268.23B | Reported |
| FY2026 Q2 | 2025. 11. 06. | Time TBD | — | $8.89 | — | — | $172.93B | Reported |
| FY2026 Q1 | 2024. 06. 30. | Time TBD | — | $7 | — | — | $79.28B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 15. | Citigroup | — | Maintain | Buy → Buy | — | Citigroup: Buy |
| 2026. 05. 12. | Wells Fargo | — | Maintain | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
| 2026. 05. 09. | UBS | — | Maintain | Buy → Buy | — | UBS: Buy |
| 2026. 05. 09. | JP Morgan | — | Maintain | Overweight → Overweight | — | JP Morgan: Overweight |
| 2026. 05. 08. | Evercore ISI Group | — | Maintain | Outperform → Outperform | — | Evercore ISI Group: Outperform |
| 2026. 04. 28. | William Blair | — | Initiate coverage | — → Outperform | — | William Blair: Outperform |
As of FY2026Q3 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 15,880 | $13.03B | 0.02% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 6,198 | $5.36B | 0.00% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 6,198 | $5.08B | 0.01% | — | New position |